Enhancing the chemosensitivity of HepG2 cells towards cisplatin by organoselenium pseudopeptides

Bioorg Chem. 2021 Apr:109:104713. doi: 10.1016/j.bioorg.2021.104713. Epub 2021 Feb 9.

Abstract

Despite all recent advances in the treatment of hepatocellular carcinoma (HCC), chemotherapy resistance still represents a major challenge in its successful clinical management. Chemo-sensitization offers an attractive strategy to counter drug resistance. Herein we report the identification of novel organoselenium-based pseudopeptides as promising highly effective chemo-sensitizers in treating HCC with cisplatin. A series of functionalized pseudopeptide- (5-9 and 17-19), peptidomimetic- (10-12 and 20-23), and tetrazole-based (13-16 and 24-27) organoselenium compounds were synthesized via isonitrile-based multicomponent reactions from two novel selenium-containing isocyanides. All compounds were evaluated for their cytotoxicity against HepG2 and the non-cytotoxic doses were used to restor the sensitivity of the cells to cisplatin. New organoselenium compounds (7, 9, 15, or 23) led to an effective chemo-sensitization of HepG2 cells towards cisplatin (up-to 27-fold). Cell cycle studies indicate that the most potent peptidomimetic diselenide 23 arrested cells at the S phase and induced apoptosis via ROS modulation.

Keywords: Chemo-sensitization; Hepatocellular carcinoma; Isocyanide; Multicomponent reactions; Organoselenium.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Cell Survival / drug effects
  • Cisplatin / pharmacology*
  • Drug Resistance, Neoplasm / drug effects
  • Hep G2 Cells
  • Humans
  • Organoselenium Compounds / pharmacology*
  • Reactive Oxygen Species

Substances

  • Antineoplastic Agents
  • Organoselenium Compounds
  • Reactive Oxygen Species
  • Cisplatin